Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung

INTRODUCTION: Azithromycin (AZM) reduces pulmonary inflammation and exacerbations in patients with COPD having emphysema. The antimicrobial effects of AZM on the lower airway microbiome are not known and may contribute to its beneficial effects. Here we tested whether AZM treatment affects the lung...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Thorax
Prif Awduron: Segal, Leopoldo N, Clemente, Jose C, Wu, Benjamin G, Wikoff, William R, Gao, Zhan, Li, Yonghua, Ko, Jane P, Rom, William N, Blaser, Martin J, Weiden, Michael D
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Publishing Group 2017
Pynciau:
Chronic Obstructive Pulmonary Disease
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5329050/
https://ncbi.nlm.nih.gov/pubmed/27486204
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2016-208599
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg